New oral treatment targeting gut healing for ulcerative colitis
Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapy
This study is testing a new oral treatment made from a modified cholera vaccine protein to help heal the gut lining in people with ulcerative colitis who haven't found relief with current medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-10596495 on NIH RePORTER |
What this research studies
This research investigates a novel oral therapeutic protein designed to promote healing of the gut lining in patients with ulcerative colitis (UC). The approach involves a modified cholera vaccine protein that has shown promise in preclinical models for enhancing epithelial repair and reducing inflammation. By administering this protein orally, the research aims to provide a new treatment option for patients who do not respond to existing UC medications. The study will optimize and validate the effectiveness of this therapy in preclinical models before considering human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with ulcerative colitis who have not achieved adequate healing with current therapies.
Not a fit: Patients with ulcerative colitis who are already responding well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new oral treatment that significantly improves mucosal healing in ulcerative colitis patients.
How similar studies have performed: Previous research has shown success with similar therapeutic approaches using modified proteins for gut healing, indicating potential for this novel treatment.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Matoba, Nobuyuki — University of Louisville
- Study coordinator: Matoba, Nobuyuki
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.